Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a business update conference call and webcast to discuss operational updates, growth strategy, and financial results for the fourth quarter and full year 2023.

Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-26-2024-302086643.html

SOURCE Lucid Diagnostics

FAQ

When will Lucid Diagnostics Inc. host the business update conference call and webcast?

Lucid Diagnostics Inc. will host the business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET.

Who will provide the business update during the conference call?

Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide the business update.

Who will discuss the financial results during the conference call?

Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.

How can listeners access the webcast?

Listeners can access the webcast at the investor relations section of the Company's website at luciddx.com.

How can U.S.-based callers access the conference call by telephone?

U.S.-based callers should dial 1-800-836-8184 to access the conference call by telephone.

How long will the replay of the conference call be available?

A replay of the conference call will be available for 30 days on the investor relations section of the Company's website at luciddx.com.